Adalimumab biosimilar - Pfizer

Drug Profile

Adalimumab biosimilar - Pfizer

Alternative Names: PF-06410293

Latest Information Update: 11 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pfizer
  • Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antipsoriatics; Antirheumatics; Eye disorder therapies; Skin disorder therapies
  • Mechanism of Action Immunomodulators; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Rheumatoid arthritis

Most Recent Events

  • 13 Jun 2018 Adverse events, efficacy and immunogenicity data from the phase III REFLECTIONS B538-02 trial in Rheumatoid arthritis presented at the 19th Annual Congress of the European League Against Rheumatism (EULAR-2018)
  • 06 Dec 2017 Pfizer completes the phase III REFLECTIONS B538-02 trial in Rheumatoid arthritis (Combination therapy, Treatment-experienced) in Australia, Brazil, Bulgaria, Canada, Colombia, Croatia, Czech Republic, Estonia, France, Georgia, Germany, Hungary, Japan, Lithuania, Mexico, New Zealand, Peru, Poland, Russia, Serbia, South Africa, South Korea, Spain, Taiwan, USA, Ukraine, United Kingdom (SC) (NCT02480153)
  • 01 May 2016 Pfizer completes a phase I comparative pharmacokinetics trial in healthy subjects in USA (NCT02572245)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top